197 related articles for article (PubMed ID: 25533565)
21. [Prevention of hypoglycemia in patients with type 1 diabetes].
Radermecker RP; Jandrain B; Paquot N; Philips JC; Contessi E; Lavigne M; Rinaldi AM; Scheen AJ
Rev Med Liege; 2003 Jun; 58(6):361-8. PubMed ID: 12945232
[TBL] [Abstract][Full Text] [Related]
22. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
[TBL] [Abstract][Full Text] [Related]
23. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.
Edelman SV; Weyer C
Diabetes Technol Ther; 2002; 4(2):175-89. PubMed ID: 12079621
[TBL] [Abstract][Full Text] [Related]
24. Insulin detemir: a new basal insulin analogue.
Soran H; Younis N
Diabetes Obes Metab; 2006 Jan; 8(1):26-30. PubMed ID: 16367879
[TBL] [Abstract][Full Text] [Related]
25. Pathophysiology and management of recurrent hypoglycaemia and hypoglycaemia unawareness in diabetes.
de Galan BE; Schouwenberg BJ; Tack CJ; Smits P
Neth J Med; 2006 Sep; 64(8):269-79. PubMed ID: 16990690
[TBL] [Abstract][Full Text] [Related]
26. Counter-regulatory hormone responses to spontaneous hypoglycaemia during treatment with insulin Aspart or human soluble insulin: a double-blinded randomized cross-over study.
Brock Jacobsen I; Vind BF; Korsholm L; Flyvbjerg A; Frystyk J; Holst JJ; Beck-Nielsen H; Henriksen JE
Acta Physiol (Oxf); 2011 Jul; 202(3):337-47. PubMed ID: 21481195
[TBL] [Abstract][Full Text] [Related]
27. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
Østoft SH
Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
[TBL] [Abstract][Full Text] [Related]
28. The effect of pramlintide on hormonal, metabolic or symptomatic responses to insulin-induced hypoglycaemia in patients with type 1 diabetes.
Amiel SA; Heller SR; Macdonald IA; Schwartz SL; Klaff LJ; Ruggles JA; Weyer C; Kolterman OG; Maggs DG
Diabetes Obes Metab; 2005 Sep; 7(5):504-16. PubMed ID: 16050943
[TBL] [Abstract][Full Text] [Related]
29. Benefits of timely basal insulin control in patients with type 2 diabetes.
Lovre D; Fonseca V
J Diabetes Complications; 2015 Mar; 29(2):295-301. PubMed ID: 25536866
[TBL] [Abstract][Full Text] [Related]
30. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M
Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093
[TBL] [Abstract][Full Text] [Related]
31. Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.
McCall AL; Farhy LS
Minerva Endocrinol; 2013 Jun; 38(2):145-63. PubMed ID: 23732369
[TBL] [Abstract][Full Text] [Related]
32. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
[TBL] [Abstract][Full Text] [Related]
33. Nocturnal hypoglycemia in patients with insulin-treated diabetes.
Yale JF
Diabetes Res Clin Pract; 2004 Sep; 65 Suppl 1():S41-6. PubMed ID: 15315870
[TBL] [Abstract][Full Text] [Related]
34. Effect of Repeated Glucagon Doses on Hepatic Glycogen in Type 1 Diabetes: Implications for a Bihormonal Closed-Loop System.
Castle JR; El Youssef J; Bakhtiani PA; Cai Y; Stobbe JM; Branigan D; Ramsey K; Jacobs P; Reddy R; Woods M; Ward WK
Diabetes Care; 2015 Nov; 38(11):2115-9. PubMed ID: 26341131
[TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort.
Dornhorst A; Lüddeke HJ; Sreenan S; Koenen C; Hansen JB; Tsur A; Landstedt-Hallin L
Int J Clin Pract; 2007 Mar; 61(3):523-8. PubMed ID: 17313628
[TBL] [Abstract][Full Text] [Related]
36. Diabetes technology and treatments in the paediatric age group.
Shalitin S; Peter Chase H
Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
[TBL] [Abstract][Full Text] [Related]
37. Hypoglycaemia awareness and counter-regulation in type 1 diabetes.
Smith U
Int J Clin Pract Suppl; 2000 Sep; (112):33-7. PubMed ID: 11064949
[No Abstract] [Full Text] [Related]
38. [Potential of a GLP-1 receptor agonist combined with basal insulin in the treatment of type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Suisse; 2014 Aug; 10(439):1549-54. PubMed ID: 25272672
[TBL] [Abstract][Full Text] [Related]
39. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial.
Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T
Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393
[TBL] [Abstract][Full Text] [Related]
40. Stability of Commercially Available Glucagon Formulation for Dual-Hormone Artificial Pancreas Clinical Use.
Taleb N; Coriati A; Khazzaka C; Bayonne J; Messier V; Rabasa-Lhoret R
Diabetes Technol Ther; 2017 Oct; 19(10):589-594. PubMed ID: 28846447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
